Francis A. Farraye, MD
Boston University School of Medicine
Dept of Medicine

MD, Albert Einstein College of Medicine
MSc, Harvard School of Public Health

Dr. Farraye’s clinical interests are in the care of patients with inflammatory bowel disease and the management of colon polyps and colorectal cancer. He is studying Vitamin D absorption in patients with IBD, the management and diagnosis of dysplasia and cancer in patients with IBD, and predictors of pouchitis after ileal pouch-anal anastomosis (IPAA). In the area of colorectal cancer, he is examining the role of hyperplastic polyps as an alternative pathway in the development of colorectal cancer.

Active Staff Privileges
Boston Medical Center

A Phase III, Open-Label Study to Determine the Long-Term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn's Disease
04/01/2009 - 09/30/2017 (PI)
Millennium Pharmaceuticals, Inc.

PUCCINI-Prospective Cohort of Ulcerative Colitis and Crohn's Disease Patients Undergoing Surgery to Identify Risk Factors for Post-Operative Infection I
06/23/2014 - 07/01/2017 (PI)
Icahn School of Medicine at Mount Sinai Crohns & Colitis Fdn

A Study to Assess the Association of Clinical outcome with serum drug concentration levels and anti-drug antibody in moderately to severely active Crohn's Disease patients treated with Adalimumab prot
08/01/2011 - 07/31/2012 (PI)
Prometheus Laboratories, Inc.

01/01/2011 - 12/31/2011 (PI)
Prometheus Laboratories, Inc.

C13006, A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study for the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Modera
04/01/2009 - 05/31/2011 (PI)
Millennium Pharmaceuticals, Inc.

A Phase IIIb Multi-Center, Double-Blind, Placebo-Controlled, Randomized Trial to Examine the Corticosteroid-Sparing Effects of Certolizumab Pegol in Patients with Moderate to Severe Crohn’s Disease (COSPAR I)
11/06/2006 - 11/05/2008 (PI)
UCB Pharma, Inc.

A Multi-Center, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients with Moderate to Severe Crohn’s Disease with Previous Exposure to Infliximab
12/08/2006 - 06/07/2007 (PI)
Abbott Laboratories

A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate for the Induction of Clinical Response in Patients with Crohn’s Disease
10/06/2005 - 10/05/2006 (PI)
Synta Pharmaceuticals Corporation

An Eight-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of Talnetant in Subjects with Irritable Bowel Syndrome
11/04/2004 - 07/19/2005 (PI)
GlaxoSmithKline, Inc.

A Phase I/IIa Trial of STA-5326 in Crohn’s Disease Patients With CDAI Scores of 220-400
06/01/2004 - 05/31/2005 (PI)
Synta Pharmaceuticals Corporation

Showing 10 of 13 results. Show All Results

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Invest to Invest…
10/03/2016 - 10/02/2018 (PI)
Celgene Corporation

An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Ac…
10/08/2015 - 09/30/2018 (PI)
Takeda Pharmaceuticals

A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Sev…
09/22/2016 - 09/21/2018 (PI)
Celgene International II Sarl

EH-5151- Evaluating the Nutritional Impact of Serum-Derived Bovine Immunoglobulin / Protein Isola…
07/25/2016 - 07/24/2018 (PI)
Entera Health, Inc.

Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)
06/23/2016 - 06/22/2018 (PI)
Beth Israel

Entyvio (velolizumab) long-term safety study
04/12/2016 - 03/31/2018 (PI)
Takeda Pharmaceuticals

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Ind…
03/31/2016 - 03/31/2018 (PI)
Celgene International II Sarl

Sample Collection Study to Evaluate DNA Markers in Subjects with Inflammatory Bowel Disease (IBD)…
12/22/2014 - 10/10/2017 (PI)
Exact Sciences

Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease:OCEANIA Study
12/12/2014 - 06/30/2017 (PI)
Exact Sciences

A Prospective, Randomized,Double Blinded, Placebo-Controlled Phase II Clinical Study of Trichuris…
05/01/2014 - 12/31/2015 (PI)
Duke University NIH-NIAID

Showing 10 of 15 results. Show All Results

Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Apte M, Reich J, Zahorian T, Farraye FA. Improving Vaccination Rates for IBD Patients Through the Use of Local Pharmacies. Inflamm Bowel Dis. 2018 Jun 09. PMID: 29893866.
  2. Szeto W, van der Bent A, Petty CR, Reich J, Farraye F, Fishman LN. Use of Social Media for Health-Related Tasks by Adolescents With Inflammatory Bowel Disease: A Step in the Pathway of Transition. Inflamm Bowel Dis. 2018 May 18; 24(6):1114-1122. PMID: 29788360.
  3. Limdi JK, Farraye FA. An Update on Surveillance in Ulcerative Colitis. Curr Gastroenterol Rep. 2018 Mar 07; 20(2):7. PMID: 29516293.
  4. Naidu H, Szeto W, Kissin E, Farraye FA. MAGIC Syndrome in a Patient With Crohn's Disease. Inflamm Bowel Dis. 2018 Feb 15; 24(3):664-665.View Related Profiles. PMID: 29462377.
  5. Pratt PK, David N, Weber HC, Little FF, Kourkoumpetis T, Patts GJ, Weinberg J, Farraye FA. Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab Therapy. Inflamm Bowel Dis. 2018 Jan 18; 24(2):380-386.View Related Profiles. PMID: 29361083.
  6. Rohde JA, Wang Y, Cutino CM, Dickson BK, Bernal MC, Bronda S, Liu A, Priyadarshini SI, Guo L, Reich JS, Farraye FA. Impact of Disease Disclosure on Stigma: An Experimental Investigation of College Students' Reactions to Inflammatory Bowel Disease. J Health Commun. 2018; 23(1):91-97. PMID: 29283816.
  7. Groshek J, Basil M, Guo L, Parker Ward S, Farraye FA, Reich J. Media Consumption and Creation in Attitudes Toward and Knowledge of Inflammatory Bowel Disease: Web-Based Survey. J Med Internet Res. 2017 Dec 08; 19(12):e403. PMID: 29222081.
  8. Saxena AP, Limdi JK, Farraye FA. Zeroing in on endoscopic and histologic mucosal healing to reduce the risk of colorectal neoplasia in inflammatory bowel disease. Gastrointest Endosc. 2017 12; 86(6):1012-1014.View Related Profiles. PMID: 29146080.
  9. Reich J, Wasan SK, Farraye FA. Vaccination and Health Maintenance Issues to Consider in Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2017 Dec; 13(12):717-724.View Related Profiles. PMID: 29339947.
  10. Fine S, Nee J, Thakuria P, Duff B, Farraye FA, Shah SA. Ocular, Auricular, and Oral Manifestations of Inflammatory Bowel Disease. Dig Dis Sci. 2017 Dec; 62(12):3269-3279. PMID: 29064013.
Showing 10 of 238 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 238 publications over 29 distinct years, with a maximum of 22 publications in 2013

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Colon Cancer
Colon Polyps
Crohn’s Disease
Ileal Pouch Anal Anastomosis
Inflammatory Bowel Disease
Ulcerative Colitis
Vitamin D

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:

85 E. Concord St
Boston MA 02118
Google Map

Farraye's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department